

Clerk of the House of Representatives
 Legislative Resource Center
 B-106 Cannon Building
 Washington, DC 20515

Secretary of the Senate
 Office of Public Records
 232 Hart Building
 Washington, DC 20510

SECRETARY OF THE SENATE

04 AUG -6 AM 11:2

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Ryan, Phillips, Utrecht, & MacKinnon			
2. Address <input type="checkbox"/> Check if different than previously reported 1133 Connecticut Avenue, NW, Suite 300			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20036			
4. Contact Name Rodney Hoppe	Telephone 202-293-1177	E-mail (optional)	5. Senate ID
7. Client Name <input type="checkbox"/> Self Pfizer Inc.			6. House ID 30680

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> \$ <u>80,000</u> <small>Income (nearest \$20,000)</small></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> \$ _____ <small>Expenses (nearest \$20,000)</small></p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA defined in section 6001(b)(1)(A) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6001(b)(1)(B) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 6001(b)(1)(C) of the Internal Revenue Code</p>
--	--

Signature Rodney C. Hoppe

8/2/04

Printed Name and Title Rooney Hoppe, Partner 6 /

LD-2 (REV. 6/98)

Registrant Name Ryan, Phillips, Utrecht & MacKinnon Client Name Pfizer Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

- H.R. 3865, Prescription Drug Safety and Affordability Act of 2004
- H.R. 3662, State and Local access to Fair Prescription Drug Prices Act
- H.R. 3767, Medicare Prescription Drug Savings and Choice Act of 2004

17. House(s) of Congress and Federal Agencies contacted Check if None

- U.S. House
- U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasapoli	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Registrant Name Ryan, Phillips, Utrecht & MacKinnon Client Name Pfizer Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (One per page)

16. Specific lobbying issues

- Legislation on issues pertaining to proposed Medical Prescription Drug Benefits.
- Legislation on issues regarding FDA regulation of prescription drugs.
- H.R. 2427, Pharmaceutical Market Access Act of 2003, all provisions
- S. 778, Medicare Rx Drug Discount and Security Act of 2003, all provisions
- H.R. 1298, United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003

17. House(s) of Congress and Federal Agencies contacted Check if None

- U.S. House
- U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Berzok	
Rodney Hoppe	
Jeffrey M. MacKinnon	
William D. Phillips	
Mark Planning	
Thomas M. Ryan	
Joseph V. Vasapoli	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature

Date

